Biomea Fusion reports blood sugar control with icovamenib in type 2 diabetes study
Mid-stage trial results show sustained blood sugar reduction and potential benefit for patients unresponsive to GLP-1 therapies
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.